ArticleDiabetes, obesity & metabolism2021

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.

Moshe Phillip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.